1. 1. EMA/CHMP/148113/2016 Committee for Medicinal Products for Human Use (CHMP); 2016.
2. 2. Vena GA, Cassano N: Drugfocus: adalimumab in the treatment of moderate to severe psoriasis. Biologics 2007;1:93-103.
3. 3. Anolik JH, Owen T, Barnard J. Anti-tumor necrosis factor therapy in rheumatoid arthritis alters B lymphocytes dynamics. Arthritis Rheum 2005;52:677.
4. : Tumor necrosis factor antagonist mechanisms of action: a comprehensive review;Tracey;Pharmacol Ther,2008
5. Lafuente-Urrez RF, Perez-Pelegay J: Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: A retrospective study of 30 patients in Daily practice;5;Eur J Dermatol,2014